Recombinant Human uPAR Protein (His Tag)

Beta LifeScience SKU/CAT #: BLPSN-4742

Recombinant Human uPAR Protein (His Tag)

Beta LifeScience SKU/CAT #: BLPSN-4742
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Tag His
Host Species Human
Accession Q03405
Synonym CD87, U-PAR, UPAR, URKR
Background Urokinase plasminogen activator (uPA) and/or its receptor (uPAR) are essential for metastasis, and overexpression of these molecules is strongly correlated with poor prognosis in a variety of malignant tumours. uPAR and uPA levels in both resected tumor tissue and plasma are of independent prognostic significance for patient survival in several types of human cancer. This system has classically been thought to drive tumor progression by mediating directed extracellular proteolysis on the surface of migrating or invading cells, and intervening with this proteolysis by targeting uPAR has been proposed to represent a novel approach for inhibiting tumor progression. uPAR, also known as PLAUR or CD87, has been implicated in the growth, metastasis, and angiogenesis of several solid and hemotologic malignancies. uPAR is a highly glycosylated, 55-6kDa integral membrane protein linked to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. It is part of a cell surface system that also consists of the serine protease uPA and several specific inhibitors (plasminogen activator inhibitors 1 and 2). Additionally, the analysis of CD87 (urokinase-type plasminogen activator receptor - uPAR) expression has a potential role in the diagnostic or prognostic work-up of several hematological malignancies, particularly acute leukemia and multiple myeloma.
Description A DNA sequence encoding the human UPAR isoform 1 (Q03405-1) (Met 1-Arg 303) without the pro peptide was expressed, with a carboxy-terminal His tag.
Source HEK293
Predicted N Terminal Leu 23
AA Sequence Met 1-Arg 303
Molecular Weight The secreted recombinant human UPAR consists of 292 a.a. with the predicted molecular mass of 32.8 kDa. As a result of glycosylation, rhUPAR migrates as an approximately 48 kDa band in SDS-PAGE under reducing conditions.
Purity >98% as determined by SDS-PAGE
Endotoxin < 1.0 EU per μg of the protein as determined by the LAL method
Bioactivity Measured by its binding ability in a functional ELISA. Immobilized human uPAR at 5 ug/ml (100 ul/well) can bind biotinylated human UPA with a linear ranger of 40-1000 ng/ml.
Formulation Lyophilized from sterile PBS, pH 7.4.
Stability The recombinant proteins are stable for up to 1 year from date of receipt at -70°C.
Usage For Research Use Only
Storage Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Target Details

Target Function Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form.
Subcellular Location Cell membrane. Cell projection, invadopodium membrane.; [Isoform 1]: Cell membrane; Lipid-anchor, GPI-anchor.; [Isoform 2]: Secreted.
Database References
Tissue Specificity Expressed in neurons of the rolandic area of the brain (at protein level). Expressed in the brain.

Gene Functions References

  1. In acutely admitted patients with COPD, elevated PLAUR levels were associated with increased risk of mortality. PMID: 29783959
  2. This study shows that the D2A sequence of the UPAR induces cell growth through alphaVbeta3 integrin and EGFR. PMID: 29184982
  3. High expression of U-PAR is associated with breast cancer. PMID: 29893327
  4. suPAR is associated with the Coronary Artery Calcification score and is a risk factor for new-onset CVD in patients undergoing hemodialysis. PMID: 29734173
  5. Elevated baseline soluble urokinase receptor concentrations independently associate with new-onset microalbuminuria in subjects at increased risk of developing type 2 diabetes. PMID: 28091558
  6. suPAR levels were significantly higher Behcet's disease patients. PMID: 27171829
  7. To develop enzyme-resistant analogues, we applied here the Retro-Inverso (RI) approach, whereby the topology of the side chains is maintained by inverting the sequence of the peptide and the chirality of all residues. Molecular dynamics suggests that peptide RI-3 adopts the turn structure typical of uPAR-FPR1 antagonists PMID: 28465589
  8. results demonstrated that PLAUR induces geftinib-resistance through EGFR/p-AKT/survivin signaling pathway in gefitinib-resistant human lung adenocarcinoma cells. PLAUR could be a novel therapeutic target for gefitinib-resistant NSCLC patients. PMID: 29961070
  9. High Upar expression is associated with breast cancer. PMID: 28498427
  10. Circulating soluble uPAR levels are higher in patients with peripheral arterial disease, particularly in those with extensive atherosclerosis and are predictive of long term cardiovascular and PAD-related outcomes. PMID: 28728756
  11. Data confirmed PLAUR and CDH11, both targets of miR-335, to be overexpressed in gastric cancer tissues. PMID: 29075357
  12. Serum and urine concentration of suPAR did not different between different clinical patterns of nephrotic syndrome in children, regardless the immunosuppressive treatment used. PMID: 29775445
  13. the present study demonstrated that EGF induced aggressiveness of gastric cancer cells by activating epithelial to mesenchymal transition, which involved the activation of the ERK1/2 pathway and, subsequently, uPAR expression PMID: 28849196
  14. The results establish GDE3 as a negative regulator of the uPAR signaling network and, furthermore, highlight GPI-anchor hydrolysis as a cell-intrinsic mechanism to alter cell behavior. PMID: 28849762
  15. uPAR and TF could potentially be attractive targets for molecular imaging and therapy in oral squamous cell carcinoma due to high positive expression rates and tumor-specific expression patterns. High uPAR expression was significantly associated with a reduced survival. PMID: 28841839
  16. suPAR levels are significantly elevated in hemodialysis patients with ESRD and remain associated with adverse outcomes. PMID: 28495863
  17. These findings may show that presenting a high level of suPAR in migraine patients with attack and aura results to predisposition to occurring on the symptoms and that high levels of suPAR, procalcitonin and fibrinogen in patients with migraine result in neurogenic inflammation during migraine headaches. PMID: 28553881
  18. suPAR may be a good novel biomarker for systemic subclinical inflammation and immune activation linked to adolescent obesity. PMID: 28749394
  19. IFN-gamma, CXCL16 and uPAR are promising as effective biomarkers of disease activity, renal damage, and the activity of pathological lesions in systemic lupus erythematosus. PMID: 28628472
  20. Main associations between PLAUR (urokinase plasminogen activator receptor) single nucleotide polymorphisms (SNPs) and markers of airway remodelling, and immunohistochemical analyses PMID: 26869673
  21. Increased uPAR expression was detected in the derma of psoriatic lesions and in the stroma surrounding tumor cells in basal cell carcinomas. PMID: 28429105
  22. Plasma plasminogen activator urokinase receptor (P-suPAR) concentrations are elevated in acute alcohol pancreatitis (AAP) and correlate with the severity of the disease, suggesting P-suPAR may serve as a prognostic marker for AAP severity on admission. PMID: 27841794
  23. We report on the impact of bispecific targeting on the toxicity risks associated with targeting of EGFR and uPAR . Our results show that eBAT is safe and potentially effective at biologically active doses despite EGFR targeting, supporting further translation for patients with sarcomas and other EGFR-expressing malignancies. PMID: 28193671
  24. Improved positron emission tomography imaging of glioblastoma cancer using novel (68)Ga-labeled peptides targeting the urokinase-type plasminogen activator receptor (uPAR). PMID: 28316028
  25. Sera and tissues from malignant mesothelioma (MM) patients showed significantly high plasminogen activator urokinase receptor (uPAR) levels, suggesting the pathogenic role of uPAR in the tumor biology of MM. PMID: 27602956
  26. Levels of circulating cleaved soluble forms plasminogen activator urokinase receptor (DIIDIII-suPAR) in acute myeloid leukemia (AML) patients are higher as compared to controls and significantly decrease after the conditioning. PMID: 27517491
  27. Serum soluble urokinase-type plasminogen activator receptor as a serum marker of inflammatory response that leads to tissue damage and surgical complication PMID: 27759946
  28. Binding of uPAR to VN triggers integrin-mediated signals, which result in ERK1-2 and RAC activation, accumulation of ROS, and senescence. PMID: 28086938
  29. Plasma levels of intact and cleaved urokinase plasminogen activator receptor do not hold important predictive or prognostic information in men with clinically localised prostate cancer. PMID: 28607123
  30. This study provides novel data that elevated airway and blood uPAR is a feature of asthma and that blood uPAR is particularly related to severe, nonatopic asthma. PMID: 27624865
  31. uPAR and mTORC2 are components of a single cell-signaling pathway. PMID: 27777073
  32. Patients with high suPAR levels were more likely to have progression of their kidney disease. PMID: 28873129
  33. Results provide evidence that uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R. PMID: 27502396
  34. PLAUR to be essential for activation of Checkpoint kinase 1 (CHK1); maintenance of cell cycle arrest after DNA damage in a TP53-dependent manner; expression, nuclear import and recruitment to DNA-damage foci of RAD51 recombinase, the principal protein involved in the homologous recombination repair pathway. PMID: 27685627
  35. The synergy of circulating factor suPAR and APOL1 G1 or G2 on alphavbeta3 integrin activation is a mechanism for CKD. PMID: 28650456
  36. Patients with cancer were significantly older and had a higher burden of comorbidities and previous cancer diagnoses compared to patients who were not diagnosed with cancer. Previous cancer, C-reactive protein (CRP) and suPAR were significantly associated with newly diagnosed cancer during follow-up in multiple logistic regression analyses adjusted for age, sex and CRP PMID: 28393357
  37. This is the first report that PGE2 -induced uPAR expression, which stimulates invasiveness of human gastric cancer AGS cells, is mediated by the EP2 receptor-dependent Src/EGFR/JNK1/2, Erk1/2/AP-1, and Src/EGFR/JNK1/2, Erk1/2/NF-kappaB cascades. PMID: 27377703
  38. Studies indicate the feasibility of combining two U-PA receptor (uPAR)-targeted probes in a preclinical head and neck cancer model. PMID: 28039488
  39. Results suggest that soluble urokinase-type plasminogen activator receptor levels are positively correlated with severity of acute pancreatitis. PMID: 27914940
  40. our study indicates that suPAR increases in patients with AML and this situation is associated with poorer survival. suPAR can thus be used as a diagnostic and prognostic biomarker in AML and may help in the developing of specific therapeutic targets. PMID: 26376588
  41. urokinase plasminogen activator receptor has a role in incidence of venous thromboembolism PMID: 26466866
  42. Our study implies that both soluble UPAR and advanced echocardiography are useful diagnostic tools for identifying patients with diabetes at risk of future clinical heart disease PMID: 26951602
  43. The effect of LIF and uPAR on trophoblast migration and invasion was mediated by PI3K/AKT signaling pathway. PMID: 27133045
  44. findings showed that elevated plasma suPAR levels were independently associated with an increased risk of developing first-time myocardial infarction in an HIV-1-infected population PMID: 26365671
  45. Soluble urokinase plasminogen activation receptor (suPAR) is an emerging new biomarker for prognosticating cardiovascular disease PMID: 27052059
  46. we review the human and mouse Ly6/uPAR family gene and protein structure and genomic organization, expression, functions, and evolution, and introduce new names for novel family members PMID: 27098205
  47. Report presence of urokinase-type plasminogen activator receptor in seminal plasma, focusing on its interesting role as reliable and sensitive marker of inflammation for the differential diagnosis of male accessory gland inflammation. PMID: 26384478
  48. uPAR expression is higher in normal pregnant women than that in patients with threatened abortion. uPAR promotes trophoblast migration and invasion during embryo implantation as well as plays a role in trophoblast differentiation into syntrophoblasts. PMID: 26823748
  49. results show that cleaved uPAR forms are significantly increased in patients with advanced prostate cancer. PMID: 26764285
  50. Hypoxia enhanced the endogenous uPAR mRNA and protein expression.HIF-1 protein bound the putative HIF-1 response element on the uPAR promoter.uPAR protein expression was detected in cervical cancer but not in normal cervix or CIN. PMID: 26718775


Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed